Oral News and Research

RSS

High levels of variability, inconsistencies found in children's medication labeling and measuring devices

An examination of 200 of the top-selling cough/cold, allergy, analgesic and gastrointestinal over-the-counter liquid medications for children finds that there have been high levels of variability and inconsistencies regarding medication labeling and measuring devices, according to a study that will appear in the December 15 issue of JAMA. The study is being released early online because of its public health importance.

1 Dec 2010

Los Angeles prosthodontist provides effective dental treatment for oral cancer patients

Oral cancer is a common condition affecting over 30,000 Americans each year. Worldwide the number falls into the hundreds of thousands, and a significant percentage of those with oral cancer end up losing teeth and normal mouth function in the absence of early cancer detection and treatment.

1 Dec 2010

Data on UCB’s anti-epileptic drugs to be presented at AES annual meeting

New data on UCB's anti-epileptic drug (AED) Vimpat (lacosamide) C-V will be presented at the 64th annual meeting of the American Epilepsy Society (AES), taking place at the San Antonio Convention Center in San Antonio, Texas from December 3 to 7, 2010. Data will also be presented on Keppra XR and the investigative epilepsy therapy, brivaracetam.

1 Dec 2010

Rush University enrolls first U.S. patient in international clinical trial for melanoma

Rush University Medical Center has just enrolled the first U.S. patient in an international clinical trial testing a novel drug to treat certain kinds of melanoma, a deadly skin cancer that in its advanced stages currently has few effective treatments.

1 Dec 2010

Pfizer awards $2.1 million grant to NCCN to evaluate axitinib in solid tumors

The National Comprehensive Cancer Network has been awarded a $2.1 million grant from Pfizer to develop a program to scientifically evaluate and define the clinical activity of axitinib in various tumor types.

1 Dec 2010

NIA awards Aphios Phase I Fast Track SBIR grant for development of novel AD nanodrug

Aphios® Corporation today announced that it was awarded Phase I of a Fast Track SBIR grant from the National Institute of Aging (NIA), National Institutes of Health (NIH) for Developing a Novel Alzheimer's Disease Nanodrug.

30 Nov 2010

Zogenix completes enrollment in ZX002 Phase 3 study for moderate to severe pain

Zogenix, Inc. today announced completion of enrollment in its open-label Phase 3 safety study (Study 802) of ZX002. ZX002 is a novel, oral, single-entity, controlled-release formulation of hydrocodone for the treatment of moderate to severe pain in patients requiring around-the-clock opioid therapy for an extended period of time.

30 Nov 2010

Plackers recommends simple steps to maintain healthy teeth, gums during stressful holiday season

Three-quarters of American adults report moderate to high stress levels in their everyday lives, and that number increases during the holiday season, according to a recent survey conducted by the American Psychological Association.

30 Nov 2010

Keryx announces positive top-line results from Zerenex Phase 3 study for hyperphosphatemia

Keryx Biopharmaceuticals, Inc. today announced positive top-line results from the Phase 3 short-term efficacy study component of its Phase 3 registration program of Zerenex (ferric citrate), the Company's ferric iron-based phosphate binder for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis.

30 Nov 2010

Cytheris' combinational therapy demonstrates possible therapeutic strategy for PML

Cytheris SA, a clinical-stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the publication of a case study report based on successful treatment of Progressive Multifocal Leukoencephalopathy (PML) with combination therapy consisting of two investigational agents, Cytheris' recombinant human interleukin-7 (CYT107) and CMX001, an investigational, oral broad-spectrum antiviral drug (Chimerix, Research Triangle Park, NC) in the Journal of Antimicrobial Chemotherapy.

30 Nov 2010

Aegerion third quarter net loss increases to $6.2 million

Aegerion Pharmaceuticals, Inc., an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, announced its financial results and business highlights for the third quarter ended September 30, 2010.

30 Nov 2010

ARIAD to present clinical data on ponatinib for CML at ASH Annual Meeting

ARIAD Pharmaceuticals, Inc. today announced that updated clinical data from a fully enrolled Phase 1 trial of its investigational, pan-BCR-ABL inhibitor, ponatinib, will be presented at the 52nd Annual Meeting of the American Society of Hematology being held in Orlando, Florida, December 4-7, 2010.

30 Nov 2010

American Red Cross announces additional $2 million to combat cholera epidemic in Haiti

The American Red Cross announced today it is committing an additional $2 million to combat an escalating cholera epidemic in Haiti that has killed more than 1,700 people and sickened more than 75,000.

30 Nov 2010

DTRA presents Outstanding Scientific Achievement award to Aduro BioTech

Aduro BioTech, a clinical-stage immunotherapy company, is pleased to announce the "Outstanding Scientific Achievement" award from the Defense Threat Reduction Agency. The award was presented at the 2010 Chemical and Biological Defense Science and Technology Conference in Orlando, Florida to Dr. Justin Skoble, Associate Director, Biodefense and Process Development at Aduro BioTech.

30 Nov 2010

Medivation, Astellas enroll 1,199 patients in MDV3100 Phase 3 AFFIRM study in advanced prostate cancer

Medivation, Inc. and Astellas Pharma Inc. today announced that patient enrollment was completed on November 15, 2010 in the Phase 3 AFFIRM study of the investigational drug MDV3100, a novel, triple-acting oral androgen receptor antagonist, in patients with advanced prostate cancer who have previously been treated with chemotherapy. The companies also announced that clinical development of MDV3100 in Japan has commenced, with the initiation of patient dosing in a Phase 1-2 clinical study.

30 Nov 2010

Apricus announces publication of NexACT technology data in Pharmaceutics Journal

Apricus Biosciences, Inc., announced today that the International Journal of Pharmaceutics, a peer reviewed journal, has published new data on the NexACT technology in their November 2010 issue, based on research conducted by, and at, the Ernest Mario School of Pharmacy, Rutgers-The State University of New Jersey in Piscataway, NJ.

30 Nov 2010

To reduce spread of HIV/AIDS, IFRC calls for more focus on IDU programs

Ahead of World AIDS Day, the International Federation of the Red Cross on Friday released a report (.pdf) calling for governments around the world to do more to help stop the spread of HIV/AIDS among populations of injecting drug users (IDUs), the Associated Press reports (Heilprin, 11/25).

30 Nov 2010

Calistoga to feature data on CAL-101 inhibitor for hematologic malignancies at ASH Annual Meeting

Calistoga Pharmaceuticals, Inc., the leader in the development of delta-isoform-selective phosphatidylinositol 3-kinase (PI3K-delta) inhibitors for the treatment of cancer and inflammatory diseases, today announced the upcoming presentation of clinical and preclinical results supporting the clinical benefit of CAL-101, an oral, PI3K-delta inhibitor, in the treatment of patients with hematologic malignancies.

30 Nov 2010

WomanCare Global expands product portfolio to include Roselle, Optinor

WomanCare Global is pleased to announce an expansion of their global product portfolio to include Roselle, a combined oral contraceptive (COC) pill containing 150 micrograms of levonorgestrel and 30 micrograms of ethinylestradiol and Optinor, a progesterone-only emergency contraception pill (ECP) containing 750 micrograms of levonorgestrel.

29 Nov 2010

USPTO awards Immunitor key patent for viral vaccine

Immune Network Ltd., advises that its potential acquisition, Immunitor USA Inc., has been issued a key patent by the U.S. Patent and Trademark Office (USPTO).

29 Nov 2010

Oral News and Research

High levels of variability, inconsistencies found in children's medication labeling and measuring devices

Los Angeles prosthodontist provides effective dental treatment for oral cancer patients

Data on UCB’s anti-epileptic drugs to be presented at AES annual meeting

Rush University enrolls first U.S. patient in international clinical trial for melanoma

Pfizer awards $2.1 million grant to NCCN to evaluate axitinib in solid tumors

NIA awards Aphios Phase I Fast Track SBIR grant for development of novel AD nanodrug

Zogenix completes enrollment in ZX002 Phase 3 study for moderate to severe pain

Plackers recommends simple steps to maintain healthy teeth, gums during stressful holiday season

Keryx announces positive top-line results from Zerenex Phase 3 study for hyperphosphatemia

Cytheris' combinational therapy demonstrates possible therapeutic strategy for PML

Aegerion third quarter net loss increases to $6.2 million

ARIAD to present clinical data on ponatinib for CML at ASH Annual Meeting

American Red Cross announces additional $2 million to combat cholera epidemic in Haiti

DTRA presents Outstanding Scientific Achievement award to Aduro BioTech

Medivation, Astellas enroll 1,199 patients in MDV3100 Phase 3 AFFIRM study in advanced prostate cancer

Apricus announces publication of NexACT technology data in Pharmaceutics Journal

To reduce spread of HIV/AIDS, IFRC calls for more focus on IDU programs

Calistoga to feature data on CAL-101 inhibitor for hematologic malignancies at ASH Annual Meeting

WomanCare Global expands product portfolio to include Roselle, Optinor

USPTO awards Immunitor key patent for viral vaccine

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News